CRC (combination with pembrolizumab) and NSCLC (combination with docetaxel) | XPORT-STP-027

This is a Phase 1, two-part, two-arm, open-label study in patients with NSCLC who have had 1 or 2 prior lines of treatment, with 1 line containing a CPI, or patients with CRC who have had 2 prior lines of treatment (oxaliplatin- and irinotecan-based) and no prior immunotherapy.

Please visit clinicaltrials.gov for more information about this study.